Angus Hamish C K, Butt A Grant, Schultz Michael, Kemp Roslyn A
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
Department of Physiology, University of Otago, Dunedin, New Zealand.
Front Med (Lausanne). 2020 Jan 17;6:334. doi: 10.3389/fmed.2019.00334. eCollection 2019.
Inflammatory Bowel Diseases (IBD) are difficult to model as freshly acquired tissues are short-lived, provide data as a snapshot in time, and are not always accessible. Many patients with IBD are non-responders to first-line treatments, and responders are prone to developing resistance to treatment over time-resulting in reduced patient quality of life, increased time to remission, and potential relapse. IBD is heterogenous and we are yet to fully understand the mechanisms of disease; thus, our ability to diagnose and prescribe optimal treatment remains ineffective. Intestinal organoids are derived from patient tissues expanded . Organoids offer unique insight into individual patient disease and are a potential route to personalized treatments. However, organoid models do not contain functional microbial and immune cell components. In this review, we discuss immune cell subsets in the context of IBD, and the requirement of immune cell and microbial components in organoid models for IBD research.
炎症性肠病(IBD)难以建模,因为新获取的组织寿命短暂,只能提供某个时间点的数据,且并非总能获取到。许多IBD患者对一线治疗无反应,而有反应的患者随着时间推移也容易产生耐药性,导致患者生活质量下降、缓解时间延长以及可能复发。IBD具有异质性,我们尚未完全了解其发病机制;因此,我们的诊断和开出最佳治疗方案的能力仍然不足。肠道类器官源自扩增的患者组织。类器官为个体患者疾病提供了独特的见解,是个性化治疗的潜在途径。然而,类器官模型不包含功能性微生物和免疫细胞成分。在本综述中,我们讨论了IBD背景下的免疫细胞亚群,以及IBD研究的类器官模型中免疫细胞和微生物成分的需求。